levoleucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   28 Trials   28 Trials   211 News 


«12345»
  • ||||||||||  leucovorin calcium / Generic mfg.
    Retrospective data, Journal, Real-World Evidence:  Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study. (Pubmed Central) -  Feb 23, 2021   
    The simultaneous combination of 5FU and folinate salt synergistically strengthens fluorouracil cytotoxic effect. In our experience, levofolinate and 5FU together in continuous infusion prolong progression free survival of patients suffering from mCRC, moreover decreasing death risk and showing a clear clinical benefit for patients, irrespective of RAS mutational status, primitive tumor side and metastases surgery.
  • ||||||||||  Levofolinate / Generic mfg., irinotecan / Generic mfg.
    [VIRTUAL] Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC). () -  Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_354;    
    Previous treatment history according to the treatment line of FOLFIRI was as follows: 2nd-line, all patients received GEM-based regimen, GEM plus nanoparticle albumin bound paclitaxel in 63 pts (98.4%) and GEM in 1 (1.6%); 3rd, GEM-based and S1 in 20 (62.5%), GEM-based and 5-FU/levofolinate/oxaliplatin (FOLFOX) in 12 (37.5%); 4th, GEM-based, FOLFOX and S-1 or other agent in 5 (83.3%), 2 GEM-based regimens and S1 in 1 (16.7%). FOLFIRI is well tolerated and effective especially in the second-line treatment for pts with gemcitabine-refractory APC.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) -  Aug 24, 2020   
    P2,  N=80, Not yet recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  CLIMB: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (clinicaltrials.gov) -  Jul 9, 2020   
    P2,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Nov 2021 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Jul 2021
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  May 27, 2020   
    P3,  N=823, Active, not recruiting, 
    N=450 --> 4 | Trial completion date: Feb 2023 --> Oct 2019 | Recruiting --> Terminated | Trial primary completion date: Feb 2022 --> Oct 2019; Insufficient Accrual Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) -  May 22, 2020   
    P2,  N=162, Not yet recruiting, 
    Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021 Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2022 --> Jun 2022
  • ||||||||||  Trial completion date, Trial primary completion date:  SENECA: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas (clinicaltrials.gov) -  Nov 20, 2019   
    P2,  N=112, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Jul 22, 2019   
    P3,  N=823, Active, not recruiting, 
    Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022 Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker:  CLIMB: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (clinicaltrials.gov) -  May 16, 2019   
    P2,  N=20, Recruiting, 
    Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Not yet recruiting --> Recruiting | Initiation date: Feb 2019 --> May 2019
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date, Metastases:  BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 7, 2019   
    P2,  N=45, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Feb 2019 --> May 2019 Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Nov 14, 2018   
    P3,  N=823, Active, not recruiting, 
    Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019 Trial completion date: May 2020 --> Mar 2020 | Trial primary completion date: May 2020 --> Mar 2020
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Trial completion, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Aug 29, 2018   
    P2,  N=84, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Jul 23, 2018   
    P3,  N=823, Active, not recruiting, 
    Initiation date: May 2018 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Oct 2019 Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Jun 6, 2018   
    P2,  N=80, Active, not recruiting, 
    Phase classification: P3 --> P2 Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Trial primary completion date, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Jan 23, 2018   
    P2,  N=80, Active, not recruiting, 
    N=60 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Apr 2018